目的评价每日使用12.5mg米非司酮治疗子宫肌瘤的效果。方法64例子宫肌瘤患者随机分为对照组和观察组,对照组采用25mg/d口服量治疗,观察组采用12.5mg/d口服量治疗。疗程结束后对两组患者的临床效果进行比较。结果以肌瘤体积缩小20%作为疗效判别指标,观察组有效率为71.88%(23/32),对照组有效率为68.75%(22/32),两组比较差异无统计学意义(P>0.05)。用药3个月后两组子宫和肌瘤体积均明显缩小,各组治疗前后对比,差异有统计学意义(P<0.001)。生殖激素如促卵泡激素(FSH)、黄体生成素(LH)、雌二醇(E2)和孕酮(P)用药前后对比,激素平均水平均下降,尤其以E2和P下降明显,各组治疗前后对比,差异显著(P<0.001);但组间对比,差异无统计学意义(P>0.05,见表1)。观察组和对照组不良反应类似,差异也不显著,而且未经治疗停药后自行恢复正常。结论每日使用12.5mg米非司酮治疗子宫肌瘤疗效佳,而且也安全,建议临床进一步推广。 Objective To evaluate the effect of daily use of 12.5 mg mifepristone in the treatment of uterine fibroids. Methods 64 patients with uterine fibroids were randomly divided into control group and observation group. The control group was treated with oral dose of 25mg / d, while the observation group was treated with oral dose of 12.5mg / d. After the end of treatment, the clinical effects of the two groups were compared. Results The effective rate of the observation group was 71.88% (23/32) and the effective rate of the control group was 68.75% (22/32). The difference between the two groups was not statistically significant (P> 0.05). After 3 months of treatment, the volume of uterus and fibroids in both groups were significantly reduced, the difference between before and after treatment was statistically significant (P <0.001). Reproductive hormones such as follicle stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2) and progesterone (P) before and after treatment, the average hormone levels were decreased, especially E2 and P decreased significantly, the treatment of each group Before and after comparison, the difference was significant (P <0.001); but there was no significant difference between groups (P> 0.05, see Table 1). Adverse reactions in the observation group and the control group were similar and the difference was not significant, and returned to normal without stopping treatment. Conclusion Daily use of 12.5mg mifepristone treatment of uterine fibroids good effect, but also safe, it is recommended further clinical.